Brian Daniels, M.D.
Senior Vice President,
Global Development and
Brian Daniels, M.D., is senior vice president, Global Development and Medical Affairs, and a member of the Senior Management Team, the company’s most senior leadership group. He has responsibility for developing innovative medicines that meaningfully improve the standard of care for patients and communicating the value of these medicines to society to ensure their safe and appropriate use.
Brian joined Bristol-Myers Squibb in 2000 as vice president of the Immunology, Pulmonary, and Dermatology therapeutic area, where he provided strategic oversight and led the early development of compounds including ORENCIA and belatacept. In 2002, he was promoted to vice president, Full Development, providing leadership to the development of six key clinical programs including REYATAZ and BARACLUDE Brian also led efforts to improve productivity and to standardize and integrate the global execution of clinical trials as vice president of Global Development Operations.
Prior to joining Bristol-Myers Squibb, Brian spent four years at Merck Research Laboratories in clinical research where he ultimately assumed the role of senior director, Pulmonary and Immunology. He has also worked in clinical research at Genentech.
Brian received his M.D. from Washington University School of Medicine and completed residencies in Internal Medicine at New York Hospital and Rheumatology at the University of California in San Francisco. He also received bachelor and master degrees in biology from the Massachusetts Institute of Technology.
Brian is involved in a variety of activities at Bristol-Myers Squibb, including the Women’s Affinity Group, the Women in Science global network, and the GDMA Next Generation Leadership Team. Outside of Bristol-Myers Squibb, Brian is on the Board of Directors for the non-profit organization, TransCelerate BioPharma. TransCelerate seeks to advance innovation in R&D, identify and solve common R&D challenges, and further improve patient safety with the goal of delivering more high quality medicines to patients.